Meeting report on the second targeted tumor therapies

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 17-23

  Bachran, Christopher ^a   Fuchs, Hendrik ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOTOXIN;

CANCER INHIBITION; CANCER THERAPY; CONFERENCE PAPER; DRUG DESIGN; GERMANY; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEOPLASM; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTOXINS; NEOPLASMS; PRODRUGS;

EID: 73949093746     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0491     Document Type: Conference Paper

References (9)

1. Cho W. Cancer research on non-small cell lung cancer in smokers and non-smokers: Snapshots from the AACR annual meeting 2009. Cancer Biol Ther 2009;8:1309-12.
2. Cho WCS. Updates in cancer research: insights from the AACR 100th Annual Meeting. Expert Rev Mol Diagn 2009;9:411-6.
3. Madhankumar AB, Slagle-Webb B, Wang X, et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther 2009;8:648-54.
4. Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009;8:1955-63.
5. Winkler J, Martin-Killias P, Plückthun A, Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009;8: 2674-83.
6. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 2009;8:1655-65.
7. Yuan X, Lin X, Manorek G, et al. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 2009;8:1906-15.
8. Mahmud H, Dälken B, Wels WS. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol Cancer Ther 2009;8:1526-35.
9. Fuchs H, Bachran C. Targeted tumor therapies at a glance. Curr Drug Targets 2009;10:89-93.